Recent reports have demonstrated that similar activation of β-catenin, either via engineered deletions or CRISPR targeting of Ctnnb1 exon 3 in the liver, is sufficient to generate tumours in mice7,8. This evidence concerns the gene CTNNB1 and neoplasm.